Recombinant Human Plasma Gelsolin
Phase 2Small molecule
Recombinant Human Plasma Gelsolin is one of 32 small molecule programs targeting Inflammatory Response. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Inflammatory Response
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Advil
KKenvue Brands
Approved
Andriol
AAuxilium
Approved
Zocor
OOrganon and Co
Approved
Clozaril
LLife Extension Foundation Inc.
Approved
Singulair
OOrganon and Co
Approved
Oxycontin
PProtega
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phase 11 trial
Inflammatory Response1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBioAegis Therapeutics Inc.